CORALVILLE — When it comes to admitting how much they smoke or drink, people aren’t always the most truthful.
IDx, a privately-held AI diagnostics company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company’s De Novo request to market IDx-DR, an AI-based diagnostic system for the autonomous detection of diabetic retinopathy, a leading cause of blindness. IDx-DR is the first autonomous, AI-based diagnostic system authorized for commercialization by the FDA.
IDx, a University of Iowa spinout company based in Coralville, has received FDA approval to market IDX-DR, the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes.
Coralville-based SynderBio was awarded the top company award at this year's Partnering For Growth Biotech Innovation Showcase held in Ankeny on Tuesday.
